EUVIMEDEUVIMED entdecken
Vergleichsstudie

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States

Sonia Graziano iD, Edwina C Landau iD, Horst Mitmansgrubert, Marieke Verkleij iD, Anna M Georgiopoulos iD, Urszula Borawska-Kowalczyk, Beth A Smith, Christina J Bathgate iD, Alexandra L Quittner iD

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71367 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Sonia Graziano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Psychology Unit, Child & Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Aminophenols, Cystic Fibrosis, Indoles, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: This study was supported also/by the Italian Ministry of Health with "Current Research funds.".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well‐being. However, there are growing concerns about side‐effects related to sleep, cognition and new, or worsening mental health in a subset. This study assessed healthcare providers' perceptions of the positive and negative impacts of ETI and compared provider ratings in Europe to the United States.

Methods

The European CF Society's Mental Health Working Group adapted and distributed the survey developed by the CF Foundation's Mental Health Advisory Committee. It assessed healthcare providers' observations of the impacts of ETI in these domains: (1) positive and negative physical and psychological effects, (2) sleep difficulties, (3) cognitive difficulties, (4) worsening mental health, and (5) concerns about the future and finances.

Results

Seventy‐eight healthcare providers across 21 European (EU) countries responded, endorsing similar percentages of positive physical and psychological effects as US providers. However, in Europe lower percentages of MH side‐effects (e.g., increased depression/anxiety, suicidal ideation, body image), and concerns about the future (e.g., copays, food insecurity) were found.

Conclusions

Across international providers similar positive results were reported. A substantial proportion of PWCF across EU and United States experienced ETI side‐effects related to sleep, cognition, and new or worsening mental health. However, EU providers reported significantly fewer side‐effects related to mental health, negative body image, planning for the future and finances. MH side‐effects led to dosing changes in ETI and in the United States, they led to changes in MH medications. These international data document the importance of systematically assessing and managing these side‐effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsCystic FibrosisIndolesQuinolonesBenzodioxolesHealth PersonnelPyrrolidinesPyridinesHumansUnited StatesEuropeDrug CombinationsMental HealthMaleFemaleSleep Wake DisordersAdultCyclopropanesSurveys and QuestionnairesPyrazolesQuinolines

Stichwörter der Autor:innen

anxietycognitive difficultiescystic fibrosisdepressionelexacaftor/tezacaftor/ivacaftormental healthsleep difficulties

Substanzen

AminophenolsDrug CombinationsIndolesQuinolonesBenzodioxolesPyrrolidinesPyridineselexacaftor, ivacaftor, tezacaftor drug combinationCyclopropanesPyrazoles

Autor:innen und Institutionen

  • Psychology Unit, Child & Adolescent Psychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • The Graub CF Center, Schneider Children's Medical Center, Pulmonary Institute, Petah Tikva, Israel.
  • Department of Psychiatry II, Medical University Innsbruck, Innsbruck, Austria.
  • Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Child and Adolescent Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cystic Fibrosis Department, Institute of Mother and Child, Warsaw, Poland.

ORCID-Profile: Sonia Graziano, Edwina C Landau, Marieke Verkleij, Anna M Georgiopoulos, Christina J Bathgate, Alexandra L Quittner

Förderung

  • This study was supported also/by the Italian Ministry of Health with "Current Research funds."

Zitieren

APA

Graziano, S., Landau, E. C., Mitmansgrubert, H., Verkleij, M., Georgiopoulos, A. M., Borawska-Kowalczyk, U., Smith, B. A., Bathgate, C. J., & Quittner, A. L. (2025). Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71367

Vancouver

Graziano S, Landau EC, Mitmansgrubert H, Verkleij M, Georgiopoulos AM, Borawska-Kowalczyk U, et al. Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71367

BibTeX
@article{Graziano2025,
  author = {Graziano, Sonia and Landau, Edwina C and Mitmansgrubert, Horst and Verkleij, Marieke and Georgiopoulos, Anna M and Borawska-Kowalczyk, Urszula and Smith, Beth A and Bathgate, Christina J and Quittner, Alexandra L},
  title = {Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71367}
}
Kostenlos starten →